Time from Second Line Chemotherapy to Autologous Transplant – Diffuse Large B-Cell Lymphoma – Methodology
|Short description of Indicator||For diffuse large B-cell lymphoma (DLBCL) patients, number of days from second line chemotherapy to autologous transplant.|
|Rationale for measurement||Wait times are reported for many cancer services (e.g., time to treatment) and can be an indicator of access. This time to transplant indicator illustrates the timeliness of access to stem cell transplant services in Ontario for people with DLBCL. The time from first salvage chemotherapy to transplant is a critical period that can influence clinical outcomes.|
|Evidence/references for rationale||There is no published information on the optimal wait times for stem cell transplant. Unnecessary delays may impact the success of the procedure and outcome for the patient. Understanding how long patients are waiting for transplant can help provincial planning efforts.|
|Calculations for the indicator||Median, interquartile range, 10th and 90th percentile days from the date of first salvage chemotherapy to the date of transplant for all people with DLBCL who received an autologous stem cell transplant.
Cases were excluded if the patient did not have a valid health insurance number.
|Standardized Rate Calculation||N/A|
|Time Frame||2014 to 2018|
|Data availability & limitations||The time to transplant depends on complete and accurate reporting of systemic treatment data and transplant data in SSOIS, and relies on the correct identification of cases (also in SSOIS). This data source is considered to be of high quality and accuracy.|